CoChat

Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder

Open access
Thase, Michael E., Gommoll, Carl, Chen, Changzheng, Kramer, Kenneth, Khan, Arif, Durgam, Suresh · 2017 · CNS Spectrums

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Objective: To evaluate the effects of levomilnacipran extended-release (ER) on suicidal ideation and behavior in adults with major depressive disorder (MDD). Methods: Post hoc analyses were conducted in patients from 4 randomized, double-blind, placebo-controlled trials and a long-term, open-label extension study of levomilnacipran ER (40-120 mg/d) in adults with MDD. Analyses included incidence of suicide-related treatment-emergent adverse events (TEAEs); incidence of Columbia–Suicide Severity Rating Scale (C-SSRS) suicidal ideation (score=1–5) and behavior (score=6-10); percent of patients who shifted from no C-SSRS suicidal ideation/behavior at baseline to suicidal ideation during treatment (worsened from score=0 to score=1–5), or vice-versa (improved from score=1-5 to score=0). Results: Suicide-related TEAEs occurred in<1% of patients in the levomilnacipran ER studies. The incidence of C-SSRS suicidal ideation was 22.2%, 23.9%, and 21.7% for placebo, short-term levomilnacipran ER, and long-term levomilnacipran ER, respectively; C-SSRS suicidal behavior was<1% in all of these groups. In the short-term studies, the percentage of patients with C-SSRS shifts were as follows: worsening from score=0 to score=1–5 (placebo, 8.6%; levomilnacipran ER, 11.0%); improvement from score=1–5 to score=0 (placebo, 24.0%; levomilnacipran ER, 27.7%). Conclusion: In adult MDD patients, the incidence of suicidal ideation and behavior was similar between placebo and short-term levomilnacipran ER as indicated by TEAE reports and C-SSRS scores. Worsening in C-SSRS scores was also similar between placebo and levomilnacipran ER. There was no indication of increased suicidality during longer courses of continued therapy. Together, these findings suggest that this medication is not associated with increased risks of suicidal ideation or behavior.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s1092852916000663

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Incidence of C-SSRS suicidal ideation at study visits. Suicidal ideation was defined as a C-SSRS score of 1 -5. Analyses were conducted in all patients from the pooled safety population and in a subset of younger adult patients, based on available C-SSRS assessments for each respective study visit. C-SSRS, Columbia -Suicide Severity Rating Scale; ER, extended-release.
FIGURE 1 Incidence of C-SSRS suicidal ideation at study visits. Suicidal ideation was defined as a C-SSRS score of 1 -5. Analyses were conducted in all patients from the pooled safety population and in a subset of younger adult patients, based on available C-SSRS assessments for each respective study visit. C-SSRS, Columbia -Suicide Severity Rating Scale; ER, extended-release.CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. 17. M. E. THASE ET AL. https://doi.org/10.1017/S1092852916000663 Published online by Cambridge University Press

Cited by

See all 6

Metadata

Authors
Thase, M. E., Gommoll, C., Chen, C., Kramer, K., Khan, A., & Durgam, S.
Affiliations
  • University of Pennsylvania (US)
  • Allergan (United States) (US)
  • Duke University (US)
Corresponding author
Thase, Michael E.
Venue
CNS Spectrums
Published
2017-05-19
Volume
22
Issue
6
Pages
475-483
ISSN
  • 1092-8529 (ISSN-L)
  • 2165-6509
OpenAlex
W2614241956
Cited by
6
References
31
Citations by year
2023: 1 · 2022: 1 · 2021: 2 · 2019: 1 · 2017: 1
FWCI
0.38
Type
journal article
Language
en
Open access
Locations
  • CNS Spectrums (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
levomilnacipran, major depressive disorder, suicidality, suicidal ideation, suicidal behavior, Columbia Suicide Severity Rating Scale, treatment-emergent adverse events, serotonin reuptake inhibitors, antidepressant safety
MeSH terms
Levomilnacipran, Antidepressive Agents, Delayed-Action Preparations, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Humans, Suicide, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Suicidal Ideation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder. https://app.cochat.ai/papers/10.1017/s1092852916000663
The paper
Thase, M. E., Gommoll, C., Chen, C., Kramer, K., Khan, A., & Durgam, S. (2017). Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder. CNS Spectrums. https://doi.org/10.1017/s1092852916000663

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.